CN103169965A - 治疗多发性硬化 - Google Patents
治疗多发性硬化 Download PDFInfo
- Publication number
- CN103169965A CN103169965A CN2013100542015A CN201310054201A CN103169965A CN 103169965 A CN103169965 A CN 103169965A CN 2013100542015 A CN2013100542015 A CN 2013100542015A CN 201310054201 A CN201310054201 A CN 201310054201A CN 103169965 A CN103169965 A CN 103169965A
- Authority
- CN
- China
- Prior art keywords
- vla
- antibody
- experimenter
- reagent
- conjunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
Description
Claims (20)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62970004P | 2004-11-19 | 2004-11-19 | |
US60/629,700 | 2004-11-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800468858A Division CN101102792A (zh) | 2004-11-19 | 2005-11-18 | 治疗多发性硬化 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103169965A true CN103169965A (zh) | 2013-06-26 |
Family
ID=36407818
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100542015A Pending CN103169965A (zh) | 2004-11-19 | 2005-11-18 | 治疗多发性硬化 |
CNA2005800468858A Pending CN101102792A (zh) | 2004-11-19 | 2005-11-18 | 治疗多发性硬化 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800468858A Pending CN101102792A (zh) | 2004-11-19 | 2005-11-18 | 治疗多发性硬化 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090202527A1 (zh) |
EP (2) | EP1827491A4 (zh) |
JP (4) | JP2008520717A (zh) |
CN (2) | CN103169965A (zh) |
AU (1) | AU2005306399B2 (zh) |
CA (1) | CA2587597A1 (zh) |
HK (1) | HK1203055A1 (zh) |
WO (1) | WO2006055871A2 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
DE602004010531T2 (de) | 2003-09-09 | 2008-07-03 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
US20090169477A1 (en) * | 2004-12-03 | 2009-07-02 | Michael Panzara | Delaying or preventing onset of multiple sclerosis |
HRP20220902T3 (hr) | 2007-02-08 | 2022-10-14 | Biogen Ma Inc. | Pripravci i njihova upotreba u liječenju multiple skleroze |
AR067011A1 (es) * | 2007-06-14 | 2009-09-30 | Biogen Idec Inc | Formulaciones de anticuerpos |
LT2558499T (lt) | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Antikūnai prieš vla-4 |
AU2014285086A1 (en) * | 2013-07-05 | 2016-01-21 | Biogen Ma Inc. | Compositions and methods for treatment of stroke |
WO2016145389A1 (en) | 2015-03-12 | 2016-09-15 | Board Of Trustees Of Michigan State University | Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases |
EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
JP2020505955A (ja) | 2017-02-06 | 2020-02-27 | オリオンズ バイオサイエンス インコーポレイテッド | 標的化改変型インターフェロン及びその使用 |
CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
US11312775B2 (en) | 2017-07-20 | 2022-04-26 | University Of Virginia Patent Foundation | Methods for treatment or prevention of a neurological immunity disorder |
MA54752A (fr) * | 2019-01-14 | 2021-11-24 | Univ Virginia Patent Foundation | Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
NZ215865A (en) * | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5217870A (en) * | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US6307025B1 (en) * | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
US5260210A (en) * | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
EP0670735B1 (en) * | 1992-11-13 | 1997-04-02 | Board Of Regents Of The University Of Washington | Peripheralization of hematopoietic stem cells |
NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
CA2155303C (en) | 1993-02-09 | 2010-04-20 | Linda C. Burkly | Treatment for insulin dependent diabetes |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6432404B1 (en) * | 1993-12-23 | 2002-08-13 | Icos Corporation | Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies |
HU220799B1 (hu) * | 1994-01-25 | 2002-05-28 | Elan Pharmaceuticals, Inc. | Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5672622A (en) * | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
CZ292465B6 (cs) | 1996-02-09 | 2003-09-17 | Abbott Laboratories (Bermuda) Ltd. | Lidské protilátky k lidskému TNFalfa |
US7361331B2 (en) * | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
US6890526B2 (en) * | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
WO1999033455A1 (en) * | 1997-12-30 | 1999-07-08 | Bioabsorbable Concepts, Inc. | Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system |
US7232830B2 (en) * | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
AU767066B2 (en) * | 1999-03-03 | 2003-10-30 | Curis, Inc. | Methods of modulating lipid metabolism and storage |
WO2001045725A2 (en) * | 1999-12-23 | 2001-06-28 | Ancile Pharmaceuticals, Inc. | Treatment for inflammatory bowel disease (ibd) and related conditions |
EP1252143A1 (en) | 2000-01-27 | 2002-10-30 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
EP1274834B1 (en) * | 2000-03-31 | 2010-07-07 | The Scripps Research Institute | HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
CN1541106A (zh) * | 2001-06-11 | 2004-10-27 | 转新疗法公司 | 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法 |
WO2003053220A2 (en) * | 2001-12-17 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US20040203031A1 (en) * | 2002-04-03 | 2004-10-14 | University Of Pennsylvania | Methods for determining drug responsiveness |
CA2476376C (en) * | 2002-02-15 | 2014-10-21 | Cornell Research Foundation, Inc. | Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
SI2336184T1 (sl) * | 2002-02-25 | 2015-04-30 | Biogen Idec Ma Inc. | Dajanje sredstev za zdravljenje vnetij |
EP1551444B1 (en) * | 2002-10-16 | 2018-03-21 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease using gm-csf |
KR101260497B1 (ko) * | 2003-01-24 | 2013-09-12 | 엘란 파마슈티칼스, 인크. | 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료 및 조성물 |
CA2515444C (en) * | 2003-02-10 | 2014-04-01 | Elan Pharmaceuticals, Inc. | Immunoglobulin formulation and method of preparation thereof |
US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
EP1735000A2 (en) * | 2004-04-16 | 2006-12-27 | Genentech, Inc. | Method for augmenting b cell depletion |
SI2322556T1 (sl) * | 2004-09-03 | 2016-02-29 | Genentech, Inc. | Humanizirani antagonisti proti beta7 in njihove uporabe |
EP1902045B1 (en) * | 2005-06-09 | 2011-01-19 | UCB Pharma, S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
CA2652434A1 (en) * | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
US20090004189A1 (en) * | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
-
2005
- 2005-11-18 EP EP05824954A patent/EP1827491A4/en not_active Ceased
- 2005-11-18 CN CN2013100542015A patent/CN103169965A/zh active Pending
- 2005-11-18 WO PCT/US2005/042052 patent/WO2006055871A2/en active Application Filing
- 2005-11-18 EP EP14174866.5A patent/EP2808033A1/en not_active Withdrawn
- 2005-11-18 CA CA002587597A patent/CA2587597A1/en not_active Abandoned
- 2005-11-18 AU AU2005306399A patent/AU2005306399B2/en not_active Ceased
- 2005-11-18 CN CNA2005800468858A patent/CN101102792A/zh active Pending
- 2005-11-18 US US11/719,660 patent/US20090202527A1/en not_active Abandoned
- 2005-11-18 JP JP2007543322A patent/JP2008520717A/ja active Pending
-
2008
- 2008-11-18 JP JP2008294839A patent/JP2009091360A/ja active Pending
-
2012
- 2012-08-29 JP JP2012188532A patent/JP2012233009A/ja active Pending
-
2014
- 2014-12-08 JP JP2014247885A patent/JP2015044873A/ja active Pending
-
2015
- 2015-04-13 HK HK15103598.3A patent/HK1203055A1/zh unknown
Non-Patent Citations (2)
Title |
---|
RICHARD A RUDICK: "Natalizumab: aplha4-integrin antagonist selective adhesion molecule inhibitors for MS", 《EXPERT REV NEUROTHERAPEUTICS》 * |
RICHARD A.RUDICK ET AL: "Study designs of two phase III trials to determine the safety and efficacy of natalizumab(Antegren®) alone and when added to interferon beta 1a(Avonex®) in patients with relapsing-remitting multiple sclerosis", 《NEUROLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
JP2015044873A (ja) | 2015-03-12 |
AU2005306399A1 (en) | 2006-05-26 |
AU2005306399B2 (en) | 2012-02-09 |
JP2009091360A (ja) | 2009-04-30 |
EP2808033A1 (en) | 2014-12-03 |
EP1827491A2 (en) | 2007-09-05 |
EP1827491A4 (en) | 2010-07-14 |
CN101102792A (zh) | 2008-01-09 |
WO2006055871A3 (en) | 2006-08-03 |
JP2008520717A (ja) | 2008-06-19 |
WO2006055871A2 (en) | 2006-05-26 |
HK1203055A1 (zh) | 2015-10-16 |
CA2587597A1 (en) | 2006-05-26 |
US20090202527A1 (en) | 2009-08-13 |
JP2012233009A (ja) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169965A (zh) | 治疗多发性硬化 | |
US9533044B2 (en) | Methods of treating inflammatory disorders using high concentration natalizumab compositions | |
WO2006023629A2 (en) | Treatment of pediatric multiple sclerosis | |
EP3202789B1 (en) | Anti-vla-4 antibodies | |
JP2008520717A5 (zh) | ||
CN101111263A (zh) | 推迟或阻止发生多发性硬化 | |
AU2012202575B2 (en) | Treatment for Multiple Sclerosis | |
AU2014203661A1 (en) | Antibody Formulations | |
CA2478456A1 (en) | Combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1186413 Country of ref document: HK |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Massachusetts, USA Applicant after: Than Ao Gen MA company Address before: Massachusetts, USA Applicant before: Biogen Idec MA Inc. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BIOGEN IDEC MA TO: BIOGEN MA INC. Free format text: CORRECT: ADDRESS; FROM: |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130626 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1186413 Country of ref document: HK |